Novo Nordisk says it’s suing Hims to halt obesity drug copycats

Hims is breaching the U.S. patent on semaglutide, the active ingredient in Novo’s blockbuster obesity treatments, Novo argued Monday.

Last updated Feb 9, 2026 by ATDb automated enrichment